IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples